Biogen Inc. (BIIB) EVP Adriana Karaboutis Sells 262 Shares of Stock
Biogen Inc. (NASDAQ:BIIB) EVP Adriana Karaboutis sold 262 shares of the business’s stock in a transaction dated Tuesday, October 4th. The stock was sold at an average price of $311.94, for a total transaction of $81,728.28. Following the sale, the executive vice president now owns 7,579 shares in the company, valued at $2,364,193.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Adriana Karaboutis also recently made the following trade(s):
- On Monday, October 3rd, Adriana Karaboutis sold 380 shares of Biogen stock. The stock was sold at an average price of $313.00, for a total transaction of $118,940.00.
Biogen Inc. (NASDAQ:BIIB) traded down 1.03% during midday trading on Friday, hitting $302.83. The stock had a trading volume of 319,265 shares. Biogen Inc. has a one year low of $223.02 and a one year high of $333.65. The stock has a 50-day moving average price of $308.72 and a 200 day moving average price of $279.34. The firm has a market cap of $66.36 billion, a PE ratio of 17.69 and a beta of 0.95.
Biogen (NASDAQ:BIIB) last issued its earnings results on Thursday, July 21st. The biotechnology company reported $5.21 EPS for the quarter, topping the consensus estimate of $4.69 by $0.52. The company earned $2.89 billion during the quarter, compared to analyst estimates of $2.79 billion. Biogen had a return on equity of 40.59% and a net margin of 33.97%. The business’s revenue was up 11.7% on a year-over-year basis. During the same quarter last year, the firm earned $4.22 EPS. On average, analysts predict that Biogen Inc. will post $20.08 earnings per share for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the company. Howard Hughes Medical Institute purchased a new position in shares of Biogen during the first quarter valued at approximately $135,000. Kings Point Capital Management purchased a new position in shares of Biogen during the second quarter valued at approximately $145,000. Signaturefd LLC raised its position in shares of Biogen by 217.7% in the second quarter. Signaturefd LLC now owns 718 shares of the biotechnology company’s stock valued at $174,000 after buying an additional 492 shares during the last quarter. Lakeview Capital Partners LLC purchased a new position in shares of Biogen during the second quarter valued at approximately $205,000. Finally, BLB&B Advisors LLC purchased a new position in shares of Biogen during the second quarter valued at approximately $206,000. Institutional investors own 86.21% of the company’s stock.
A number of analysts have issued reports on the stock. JPMorgan Chase & Co. reiterated a “buy” rating and set a $386.00 price target on shares of Biogen in a research note on Friday, September 16th. Jefferies Group reissued a “buy” rating and set a $319.00 price objective on shares of Biogen in a research report on Thursday, August 4th. Robert W. Baird reissued a “neutral” rating and set a $284.00 price objective on shares of Biogen in a research report on Wednesday, August 10th. Vetr raised Biogen from a “buy” rating to a “strong-buy” rating and set a $346.47 price objective for the company in a research report on Monday, September 12th. Finally, Piper Jaffray Cos. set a $333.00 price objective on Biogen and gave the stock a “hold” rating in a research report on Thursday, September 22nd. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Biogen has a consensus rating of “Buy” and a consensus target price of $347.34.
Biogen Inc, formerly Biogen Idec Inc, is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis.
Receive News & Stock Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related stocks with our FREE daily email newsletter.